Access Bio Inc

Access Bio Inc maintains a strong liquidity position with a current ratio of 10.11, indicating that it holds significantly more current assets than current liabilities. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The company's debt-to-equity ratio is 0.12, suggesting a conservative capital structure with limited leverage.

Profitability metrics show that Access Bio Inc has a return on equity (ROE) of 0.0045 and a return on assets (ROA) of 0.0039. These figures are below the typical thresholds for strong performance in the medical equipment and supplies industry, indicating that the company is not generating substantial returns relative to its equity and asset base.

The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to assess the concentration of revenue across different business lines or geographic markets. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue stream.

Access Bio Inc reported revenue of $26,428,840 in the latest period. The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of capital expenditures and the low level of operating cash flow suggest that the company is not currently investing heavily in expansion or new projects.

The company faces a medium liquidity risk due to its negative net cash position after subtracting total debt. While the dilution risk is currently low, the company's conservative capital structure and limited leverage may constrain its ability to raise additional capital if needed. No specific dilution sources are identified in the available data.

Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The available data is limited to basic financial metrics and does not include detailed management commentary or forward-looking guidance.

With a debt-to-equity ratio of 0.12, Access Bio maintains leverage below the 0.20 cohort median.

Access Bio demonstrates best-in-class cash conversion at 17.11, far surpassing the 0.84 cohort median.

The company faces low dilution risk, suggesting limited pressure on existing shareholder equity value.

The company reported a net loss of $57.7 million, reflecting a massive deterioration in profitability.

Free cash flow turned negative at -$47.7 million, highlighting significant cash burn and liquidity pressure.

Access Bio carries a high credit risk flag, signaling potential difficulties in meeting financial obligations.

Return on equity of 0.45% lags the 1.42% cohort median, indicating inefficient use of shareholder capital.

Revenue $962.8k, −94,8% YoY; Operating income −601,8% YoY.

• ▍Revenue $962.8k, −94,8% YoY
• ▍Operating income −601,8% YoY
• ▍Net income −752,4% YoY
• ▍Free cash flow −235,3% YoY
• ▍Net margin -766.9%

Revenue $14.9M, −43,5% YoY; Operating income −448,4% YoY.

• ▍Revenue $14.9M, −43,5% YoY
• ▍Operating income −448,4% YoY
• ▍Net income −321,6% YoY
• ▍Free cash flow −136,9% YoY
• ▍Net margin -30.3%

Revenue $26.4M; Operating income $1.6M.

• ▍Revenue $26.4M
• ▍Operating income $1.6M
• ▍Net margin 7.7%

Revenue $267.1M, −66,6% YoY; Operating income −95,0% YoY.

• ▍Revenue $267.1M, −66,6% YoY
• ▍Operating income −95,0% YoY
• ▍Net income −100,9% YoY
• ▍Free cash flow −110,9% YoY
• ▍Net margin -0.9%

Revenue $800.2M, +81,3% YoY; Operating income +59,9% YoY.

• ▍Revenue $800.2M, +81,3% YoY
• ▍Operating income +59,9% YoY
• ▍Net income +61,9% YoY
• ▍Free cash flow +85,6% YoY
• ▍Net margin 33.5%

Revenue $441.4M; Operating income $227.1M.

• ▍Revenue $441.4M
• ▍Operating income $227.1M
• ▍Net margin 37.6%